Skip to content
Terlipressin
Terlivaz (terlipressin) is a protein pharmaceutical. Terlipressin was first approved as Terlivaz on 2022-09-14.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Terlivaz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Terlipressin acetate
Tradename
Company
Number
Date
Products
TERLIVAZMallinckrodtN-022231 RX2022-09-14
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
terlivazNew Drug Application2022-09-19
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
TERLIPRESSIN ACETATE, TERLIVAZ, MALLINCKRODT IRELAND
2029-09-14ODE-406
2027-09-14NCE
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01B: Posterior pituitary lobe hormones
— H01BA: Vasopressin and analogues
— H01BA04: Terlipressin
HCPCS
No data
Clinical
Clinical Trials
78 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.0—555617
Septic shockD012772A48.31551616
Hepatorenal syndromeD006530K76.71363313
Esophageal and gastric varicesD004932EFO_0009545I85———347
Portal hypertensionD006975EFO_0000666K76.6—1—214
HemorrhageD006470MP_0001914R58———224
Acute kidney injuryD058186HP_0001919N17——1124
Liver transplantationD016031EFO_0010682—1—1—2
InfectionsD007239EFO_0000544———1—1
FibrosisD005355———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420T88.7—22——4
AscitesD001201HP_0001541R18—22——3
ShockD012769R57.1—11——2
Liver failureD017093HP_0001399K72.9—11——2
SepsisD018805A41.9—11——1
HemoptysisD006469HP_0002105R04.2——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N19—1———1
Portal pressureD017082—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute-on-chronic liver failureD065290————33
MyomaD009214D21————33
HypotensionD007022EFO_0005251I95————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTERLIPRESSIN
INNterlipressin
Description
Terlipressin is a polypeptide.
Classification
Protein
Drug classvasoconstrictors (vasopressin derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Identifiers
PDB—
CAS-ID14636-12-5
RxCUI57048
ChEMBL IDCHEMBL2135460
ChEBI ID—
PubChem CID72081
DrugBankDB02638
UNII ID7Z5X49W53P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,923 documents
View more details
Safety
Black-box Warning
Black-box warning for: Terlivaz
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
55 adverse events reported
View more details